These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15470272)

  • 21. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.
    Bergersen BM; Sandvik L; Bruun JN; Tonstad S
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):625-30. PubMed ID: 15322938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection.
    Barbaro G
    Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease?
    Mooser V
    AIDS; 2003 Apr; 17 Suppl 1():S65-9. PubMed ID: 12870532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment.
    Steinhart CR; Emons MF
    AIDS Read; 2004 Feb; 14(2):86-90, 93-5. PubMed ID: 14997864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.
    Crum-Cianflone NF; Weekes J; Bavaro M
    AIDS Patient Care STDS; 2008 Oct; 22(10):771-8. PubMed ID: 18783326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
    Thorne C; Newell ML
    Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.
    Rhew DC; Bernal M; Aguilar D; Iloeje U; Goetz MB
    Clin Infect Dis; 2003 Oct; 37(7):959-72. PubMed ID: 13130409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
    Haser GC; Sumpio B
    J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults.
    Monier PL; Wilcox R
    Am J Med Sci; 2004 Jul; 328(1):48-56. PubMed ID: 15254441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors.
    Mondy KE
    J Cardiometab Syndr; 2008; 3(2):88-92. PubMed ID: 18453808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
    Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of antiretroviral drugs: clinical review.
    Filardi PP; Paolillo S; Marciano C; Iorio A; Losco T; Marsico F; Scala O; Ruggiero D; Ferraro S; Chiariello M
    Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):238-44. PubMed ID: 19075633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly active antiretroviral therapy-related mechanisms of endothelial and platelet function alterations.
    Gresele P; Falcinelli E; Momi S; Francisci D; Baldelli F
    Rev Cardiovasc Med; 2014; 15 Suppl 1():S9-20. PubMed ID: 24987863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.